<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29241979</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-547X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>391</Volume>
            <Issue>10121</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Lancet (London, England)</Title>
          <ISOAbbreviation>Lancet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.</ArticleTitle>
        <Pagination>
          <StartPage>659</StartPage>
          <EndPage>667</EndPage>
          <MedlinePgn>659-667</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(17)33108-2</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(17)33108-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.</AbstractText>
          <AbstractText Label="METHODS">In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.</AbstractText>
          <AbstractText Label="FINDINGS">From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).</AbstractText>
          <AbstractText Label="INTERPRETATION">Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.</AbstractText>
          <AbstractText Label="FUNDING">Acerta Pharma, a member of the AstraZeneca Group.</AbstractText>
          <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: miwang@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rule</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Plymouth University Medical School, Plymouth, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zinzani</LastName>
            <ForeName>Pier Luigi</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goy</LastName>
            <ForeName>Andre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Casasnovas</LastName>
            <ForeName>Olivier</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Centre Hospitalier Universitaire (CHU) de Dijon, INSERM UMR 1231, Dijon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Stephen D</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>Fred Hutchinson Cancer Research Center, University of Washington Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Damaj</LastName>
            <ForeName>Gandhi</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d'Hématologie de Basse-Normandie, Caen, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doorduijn</LastName>
            <ForeName>Jeanette</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Erasmus Medical Centre, Rotterdam, The Netherlands; HOVON Lunenburg Lymphoma Phase I/II Consortium, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamy</LastName>
            <ForeName>Thierry</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>CHU de Rennes, Rennes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morschhauser</LastName>
            <ForeName>Franck</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Univeristé Lille, CHU Lille, EA 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Panizo</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Bijal</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>H Lee Moffitt Cancer Center, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davies</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research UK Centre, Cancer Sciences Unit, University of Southampton, Southampton, UK; Faculty of Medicine, Southampton General Hospital, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eek</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Border Medical Oncology, Wodonga, VIC, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dupuis</LastName>
            <ForeName>Jehan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Unité Hémopathies Lymphoïdes, Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacobsen</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Dana Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kater</LastName>
            <ForeName>Arnon P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>HOVON Lunenburg Lymphoma Phase I/II Consortium, Netherlands; Academic Medical Center, Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le Gouill</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>CHU de Nantes, Hotel Dieu, Nantes, France; INSERM UMR 892 Team 10, Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oberic</LastName>
            <ForeName>Lucie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Universitaire du Cancer, Oncopole Toulouse (IUCT-O), Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robak</LastName>
            <ForeName>Taduesz</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covey</LastName>
            <ForeName>Todd</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dua</LastName>
            <ForeName>Richa</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rothbaum</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slatter</LastName>
            <ForeName>J Greg</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, Redwood City, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jurczak</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Jagiellonian University, Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02213926</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA076292</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Lancet</MedlineTA>
        <NlmUniqueID>2985213R</NlmUniqueID>
        <ISSNLinking>0140-6736</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet. 2018 Feb 17;391(10121):633-634</RefSource>
          <PMID Version="1">29241978</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020522" MajorTopicYN="N">Lymphoma, Mantle-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Declaration of interests. MW reports grants and personal fees from Pharmacyclics, Janssen, and Acerta Pharma, outside the submitted work. SR reports personal fees from AstraZeneca and Acerta Pharma, outside the submitted work. PLZ reports personal fees from Celgene, Roche, Janssen, Gilead, Takeda, Servier, Bristol-Myers Squibb, and Merck, outside the submitted work. AG reports non-financial support from Celgene, Genentech, and Pharmacyclics, during the conduct of the study; and personal fees from Celgene, Pharmacyclics, Acerta Pharma, and Takeda outside the submitted work. OC reports grants, personal fees, and non-financial support from Roche, Gilead, and Takeda; personal fees and non-financial support from Bristol-Myers Squibb, MSD, and Celgene; and personal fees from AbbVie, outside the submitted work. SDS reports grants from Acerta Pharma, during the conduct of the study; and grants from Seattle Genetics, Merck Sharpe and Dohme, Janssen Research and Development, Pharmacyclics, Genentech, and Portola Pharmaceuticals, outside the submitted work. FM reports personal fees from Roche Genetech; and personal fees from Celgene, Bristol-Myers Squibb, Janssen, and Gilead, outside the submitted work. CP reports personal fees and non-financial support from MundiPharma; grants, personal fees, and non-financial support from Roche Pharma; grants and personal fees from Janssen, Bristol-Myers Squibb; personal fees from Takeda; and grants from Acerta Pharma, during the conduct of the study. BS reports personal fees from Celgene, Bayer, Amgen, Baxalta, Jazz, and Pfizer; grants from Rosetta Genomics, Clonoseq, DeBartolo Institute for Personalized Medicine, and Incyte, outside the submitted work. AD reports grants from Acerta Pharma during the conduct of the study; grants, personal fees, and non-financial support from F Hoffmann-La Roche, Celgene, Takeda Pharma, Gilead Sciences; personal fees and non-financial support from CTI BioPharma; grants from Bayer and GlaxoSmithKline; grants and personal fees from Janssen, Pfizer, and Karyopharma; personal fees and non-financial support from Mundipharma; and personal fees from Kite Pharma, outside the submitted work. JDu reports personal fees from AbbVie and Roche, outside the submitted work. EJ reports personal fees from Merck, Seattle Genetics, Spectrum, and Pharmacyclics, outside the submitted work. SLG reports personal fees and non-financial support from Roche; grants and personal fees from Janssen-Cilag; and personal fees from Celgene, outside the submitted work. TR reports grants from Acerta Pharma and Pharmacyclics, and grants and personal fees from Janssen, during the conduct of the study. WR reports personal fees and non-financial support from Acerta Pharma, is an investor in Acerta at Quogue BioVentures II, outside the submitted work, and is an inventor for acalabrutinib patents pending or issued. TC is currently employed by Acerta Pharma and is a shareholder of AstraZeneca. AH is currently an employee of Acerta Pharma; and has a patent pending for acalabrutinib. RI is currently an employee of Acerta Pharma; and has a patent pending for acalabrutinib. JGS is currently an employee of Acerta Pharma with stock options in the company. WJ reports grants from Acerta Pharma during the conduct of the study; and grants from Janssen, Merck, Gilead, TG Therapeutics, Sandoz, Pfizer, and Takeda, outside the submitted work. JDo, RD, AH, XH, RI, PP, WR, and JGS are employees of Acerta Pharma. GD, TL, RE, APK, and LO declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29241979</ArticleId>
        <ArticleId IdType="mid">NIHMS1664812</ArticleId>
        <ArticleId IdType="pmc">PMC7864374</ArticleId>
        <ArticleId IdType="doi">10.1016/S0140-6736(17)33108-2</ArticleId>
        <ArticleId IdType="pii">S0140-6736(17)33108-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol
2016; 34: 1256–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26755518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dreyling M, Ferrero S. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Haematologica
2016; 101: 104–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4938333</ArticleId>
            <ArticleId IdType="pubmed">26830211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen JB, Zain JM, Kahl BS. Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies. Am Soc Clin Oncol Educ Book
2017; 37: 512–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28561694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ML, Rule S, Martin P, et al.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med
2013; 369: 507–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513941</ArticleId>
            <ArticleId IdType="pubmed">23782157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol
2012; 31: 119–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22449073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacyclics. Imbruvica package insert. Sunnyvale, CA: Pharmacyclics, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al.
Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med
1994; 330: 1488–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8164701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Q, Zhang M, Winkelstein J, Chen SH, Ochs HD. Unique mutations of Bruton’s tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families. Hum Mol Genet
1994; 3: 1899–900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7849721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol
2015; 6: 242–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4556969</ArticleId>
            <ArticleId IdType="pubmed">26425337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O’Brien S, et al.
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med
2016; 374: 323–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamel S, Horton L, Ysebaert L, et al.
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia
2015; 29: 783–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25138588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Covey T, Gulrajan M, Krantz F, et al.
ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res
2015; 75 (suppl): 2596.</Citation>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al.
Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther
2017; 363: 240–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheson BD, Fisher RI, Barrington SF, et al.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol
2014; 32: 3059–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4979083</ArticleId>
            <ArticleId IdType="pubmed">25113753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheson BD, Pfistner B, Juweid ME, et al.
Revised response criteria for malignant lymphoma. J Clin Oncol
2007; 25: 579–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17242396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon R
Optimal two-stage designs for phase II clinical trials. Control Clin Trials
1989; 10: 1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2702835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol
1998; 16: 139–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9440735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang BY, Francesco M, De Rooij MF, et al.
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood
2013; 122: 2412–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3790509</ArticleId>
            <ArticleId IdType="pubmed">23940282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davids MS, Burger JA. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol
2012; 3 (suppl 1): 3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3404599</ArticleId>
            <ArticleId IdType="pubmed">22844583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiestner A
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica
2015; 100: 1495–507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4666325</ArticleId>
            <ArticleId IdType="pubmed">26628631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood
2007; 110: 3316–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17652619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayappa KD, Portell CA, Gordon VL, et al.
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv
2017; 1: 933–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5637393</ArticleId>
            <ArticleId IdType="pubmed">29034364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponader S, Chen SS, Buggy JJ, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood
2012; 119: 1182–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4916557</ArticleId>
            <ArticleId IdType="pubmed">22180443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Rooij MF, Kuil A, Geest CR, et al.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood
2012; 119: 2590–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22279054</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
